{"prompt": "['Figure 1', 'Study Schema', 'Neo/adjuvant treatment', '<', 'Neoadjuvant treatment + surgery', '(not part of the study)', 'Adjuvant treatment (part of the study)', '<', 'HCPQs', 'HCPQs', 'PPQ', 'TASQ IV', 'TASQ SC', 'HER2+ BC completed', 'P H IV', 'FDC SC', 'neoadjuvant', 'Arm A:', 'chemotherapy/P + H', '(3 cycles)', '(3 cycles)', 'Patient selected FDC SC or', 'R', 'surgery', 'P+ H IV (for a total of 18 cycles in', 'FDC SC', 'P H IV', 'neo/adjuvant setting)', 'Arm B:', 'n= 140', '(3 cycles)', '(3 cycles)', 'Follow-up for 3 years', 'TASQ SC', 'PPQ', 'TASQ IV', 'HCPQs', 'HCPQs', 'Treatment Cross-over Period', 'Treatment Continuation Period', 'Abbreviations: IV: intravenous; P+H: Perjeta + Herceptin; FDC SC: subcutaneously', 'administered fixed-dose combination of pertuzumab and trastuzumab; HCPQ: Healthcare', 'Professional Questionnaires; PPQ: Patient Preference Questionnaire; SC subcutaneous;', 'TASQ: Therapy Administration Satisfaction Questionnaire', 'Eligibility will be assessed within a 28-day screening period. Eligible patients will be enrolled', 'and randomly allocated in a 1:1 ratio to treatment Arm A (P+H IV followed by pertuzumab', 'and trastuzumab FDC SC) or treatment Arm B (pertuzumab and trastuzumab FDC SC', 'followed by P+H IV). Patients will be stratified according to neoadjuvant chemotherapy', 'regimen (anthracyclines + taxanes vs. carboplatin + taxanes vs. taxanes only), neoadjuvant', 'treatment response (pCR VS. non-pCR), and hormone receptor status (oestrogen receptor', '[ER]-positive and/or progesterone receptor [PgR]-positive VS. ER-negative and PgR-', 'negative). Study treatment will be initiated 2 weeks from breast cancer surgery but 9', 'weeks from the last administration of systemic neoadjuvant therapy and will be administered', 'on Day 1 of each 3-week treatment cycle. No adjuvant chemotherapy is allowed after', 'surgery, however, adjuvant hormone and/or radiation therapy are allowed.', 'Patients randomized to Arm A will receive P+H IV for three treatment cycles followed by', 'pertuzumab and trastuzumab FDC SC for three treatment cycles. Patients randomized to', 'Arm B will receive pertuzumab and trastuzumab FDC SC for three treatment cycles followed', 'by P+H IV for three treatment cycles. This period of 3+3 cycles in both treatment arms', 'constitutes the study Treatment Cross-over Period.', 'The 6 study treatment cycles of pertuzumab and trastuzumab FDC SC and P+H IV received', 'during the Treatment Cross-over Period and Perjeta and Herceptin treatment cycles', 'received in the neoadjuvant setting prior to study entry will be considered part of the total 18', 'anti-HER2 treatment cycles planned for all study patients. Following completion of the', 'Treatment Cross-over Period, patients will enter the Treatment Continuation Period wherein', 'they will receive the remaining anti-HER2 treatment cycles required to complete their 18', 'planned cycles unless disease recurrence, unacceptable toxicity or patient withdrawal from', 'treatment necessitates early treatment cessation. Study treatment during this period will be', 'either P+H IV or pertuzumab and trastuzumab FDC SC as selected by the patient at the end', 'of the Treatment Cross-over Period. See Figure 2 for examples of calculating the number of', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '37 / Protocol MO40628, Version 12']['study treatment cycles required during the Treatment Continuation Period. Patients will be', 'followed for at least three years from randomization (the Follow-up Period) during which time', 'they should be assessed at least every six months.', 'Figure 2 Study Treatment Cycle Calculation', 'OLD FIGURE', 'Neoadjuvant Cycles (x cycles)+ Study Treatment Cross-over (6 cycles) + Study Treatment Continuation (y cycles) = 18', 'Cycles Anti-HER2 therapy.', 'X+6+Y= 18', 'Example 1', 'Pre-Study', 'On Study', 'Neoadjuvant Treatment', 's', 'Adjuvant Treatment', 'u', 'r', 'Treatment Cross-over Period', 'Treatment Continuation Period', '3 Cycles', 'g', 'e', '6 Cycles', '9 Cycles', 'Perjeta IV and Herceptin IV/SC', 'r', '(3 Cycles P+H IV & 3 Cycles FDC SC)', 'P + H IV or FDC SC', 'y', 'Example 2', 'Pre-Study', 'On Study', 'Neoadjuvant Treatment', 's', 'Adjuvant Treatment', 'u', 'r', 'Treatment Cross-over Period', 'Treatment Continuation Period', '8 Cycles', 'g', '6 Cycles', '6 Cycles', 'Perjeta IV and Herceptin IV/SC', 'e', '(3 Cycles P + H IV & 3 Cycles FDC SC)', 'P + H IV or FDC SC', 'r', 'y', 'NEW FIGURE', 'Neoadjuvant Cycles (x cycles) + Study Treatment Cross-over (6 cycles) + Study Treatment Continuation (y cycles)', '= 18 Cycles Anti-HER2 therapy', 'X + 6 + Y 18', 'Example 1', 'Pre-Study', 'On Study', 'S', 'Neoadjuvant Treatment', 'Adjuvant Treatment', 'u', 'r', 'Treatment Cross-over Period', 'Treatment Continuation Period', 'g', '3 Cycles', 'e', '6 Cycles', '9 Cycles', 'Perjeta IV and Herceptin IV/SC', '(3 Cycles P + H IV & 3 Cycles FDC SC)', '+HIV or FDC SC', 'r', 'y', 'Example 2', 'Pre-Study', 'On Study', 'Neoadjuvant Treatment', 'S', 'Adjuvant Treatment', 'u', 'r', 'Treatment Cross-over Period', 'Treatment Continuation Period', '8 Cycles', 'g', '6 Cycles', '4 Cycles', 'Perjeta IV and Herceptin IV/SC', 'e', '(3 Cycles P + H IV & 3 Cycles FDC SC)', 'P HIV or FDC SC', 'r', 'y', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '38 / Protocol MO40628, Version 12']\n\n###\n\n", "completion": "END"}